title: Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
abstract: The second scientific workshop of the European Crohn's and Colitis Organization (ECCO) focused on the relevance of intestinal healing for the disease course of inflammatory bowel disease (IBD). The objective was to better understand basic mechanisms, markers for disease prediction, detection and monitoring of intestinal healing, impact of intestinal healing on the disease course of IBD as well as therapeutic strategies. The results of this workshop are presented in four separate manuscripts. This section describes basic mechanisms of intestinal healing, identifies open questions in the field and provides a framework for future studies.
authors.affiliation: Department of Gastroenterology & Hepatology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, USA. riederf@ccf.org
authors.forename: Florian
authors.initials: F
authors.lastname: Rieder
authors.forename: Thomas
authors.initials: T
authors.lastname: Karrasch
authors.forename: Shomron
authors.initials: S
authors.lastname: Ben-Horin
authors.forename: Anja
authors.initials: A
authors.lastname: Schirbel
authors.forename: Robert
authors.initials: R
authors.lastname: Ehehalt
authors.forename: Jan
authors.initials: J
authors.lastname: Wehkamp
authors.forename: Colin
authors.initials: C
authors.lastname: de Haar
authors.forename: Dominique
authors.initials: D
authors.lastname: Velin
authors.forename: Giovanni
authors.initials: G
authors.lastname: Latella
authors.forename: Franco
authors.initials: F
authors.lastname: Scaldaferri
authors.forename: Gerhard
authors.initials: G
authors.lastname: Rogler
authors.forename: Peter
authors.initials: P
authors.lastname: Higgins
authors.forename: Miquel
authors.initials: M
authors.lastname: Sans
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001379:Azathioprine / Q000494:pharmacology; D020148:Butyric Acid / Q000494:pharmacology; D003093:Colitis, Ulcerative / Q000235:genetics / Q000503:physiopathology*; D003424:Crohn Disease / Q000235:genetics / Q000503:physiopathology*; D016572:Cyclosporine / Q000494:pharmacology; D023082:Defensins / Q000502:physiology; D005109:Extracellular Matrix / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000473:pathology* / Q000503:physiopathology*; D020738:Leptin / Q000502:physiology; D020782:Matrix Metalloproteinases / Q000502:physiology; D019804:Mesalamine / Q000494:pharmacology; D019879:Paneth Cells / Q000502:physiology; D019936:Probiotics / Q000494:pharmacology; D026361:Reactive Nitrogen Species / Q000502:physiology; D017382:Reactive Oxygen Species / Q000378:metabolism; D012460:Sulfasalazine / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology*
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D023082:Defensins; D007166:Immunosuppressive Agents; D020738:Leptin; D026361:Reactive Nitrogen Species; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; D020148:Butyric Acid; D012460:Sulfasalazine; D019804:Mesalamine; D016572:Cyclosporine; D000069285:Infliximab; D020782:Matrix Metalloproteinases; D001379:Azathioprine